Agios Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering

Agios Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering

Firm News

Agios Pharmaceuticals, Inc. announced that it has issued an additional 757,575 shares of common stock at the public offering price of $49.50 per share, for total gross proceeds of approximately $37 million, pursuant to the exercise in full of the underwriters' over-allotment option in connection with the company's previously announced public offering of common stock. After giving effect to the full exercise of the over-allotment option, the total number of shares sold by Agios in the public offering was 5,808,080 shares and gross proceeds were approximately $287 million.

The WilmerHale deal team representing Agios included Steve Singer, Cynthia Mazareas, Emily Gainor, and Killian Nolan.

Read Agios' press release for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.